Inhibition of Neuronal Nicotinic Acetylcholine Receptor Subtypes by α-Conotoxin GID and Analogues

被引:35
作者
Millard, Emma L. [1 ,2 ]
Nevin, Simon T. [2 ]
Loughnan, Marion L. [1 ]
Nicke, Annette [3 ]
Clark, Richard J. [1 ]
Alewood, Paul F. [1 ]
Lewis, Richard J. [1 ]
Adams, David J. [2 ]
Craik, David J. [1 ]
Daly, Norelle L. [1 ]
机构
[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia
[2] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia
[3] Max Planck Inst Brain Res, D-60528 Frankfurt, Germany
基金
英国医学研究理事会; 澳大利亚研究理事会;
关键词
NMR STRUCTURE CALCULATION; TORSION ANGLE DYNAMICS; XENOPUS-LAEVIS OOCYTES; CRYSTAL-STRUCTURE; HOMOLOG ACHBP; ANTAGONISTS; BINDING; DETERMINANTS; CARCINOMA; PROTEINS;
D O I
10.1074/jbc.M804950200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
alpha-Conotoxins are small disulfide-rich peptides from the venom of the Conus species that target the nicotinic acetylcholine receptor (nAChR). They are valuable pharmacological tools and also have potential therapeutic applications particularly for the treatment of chronic pain. alpha-Conotoxin GID is isolated from the venom of Conus geographus and has an unusual N-terminal tail sequence that has been shown to be important for binding to the alpha 4 beta 2 subtype of the nAChR. To date, only four conotoxins that inhibit the alpha 4 beta 2 subtype have been characterized, but they are of considerable interest as it is the most abundant nAChR subtype in the mammalian brain and has been implicated in a range of diseases. In this study, analysis of alaninescan and truncation mutants of GID reveals that a conserved proline in alpha-conotoxins is important for activity at the alpha 7, alpha 3 beta 2, and alpha 4 beta 2 subtypes. Although the proline residue was the most critical residue for activity at the alpha 3 beta 2 subtype, Asp3, Arg12, and Asn14 are also critical at the alpha 7 subtype. Interestingly, very few of the mutations tested retained activity at the alpha 4 beta 2 subtype indicating a tightly defined binding site. This lack of tolerance to sequence variation may explain the lack of selective ligands discovered for the alpha 4 beta 2 subtype to date. Overall, our findings contribute to the understanding of the structureactivity relationships of alpha-conotoxins and may be beneficial for the ongoing attempts to exploit modulators of the neuronal nAChRs as therapeutic agents.
引用
收藏
页码:4944 / 4951
页数:8
相关论文
共 39 条
[1]   RAPID ANALYSIS OF AMINO-ACIDS USING PRE-COLUMN DERIVATIZATION [J].
BIDLINGMEYER, BA ;
COHEN, SA ;
TARVIN, TL .
JOURNAL OF CHROMATOGRAPHY, 1984, 336 (01) :93-104
[2]   A new alpha-conotoxin which targets alpha 3 beta 2 nicotinic acetylcholine receptors [J].
Cartier, GE ;
Yoshikami, DJ ;
Gray, WR ;
Luo, SQ ;
Olivera, BM ;
McIntosh, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) :7522-7528
[3]   Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an α-conotoxin PnIA variant [J].
Celie, PHN ;
Kasheverov, IE ;
Mordvintsev, DY ;
Hogg, RC ;
van Nierop, P ;
van Elk, R ;
van Rossum-Fikkert, SE ;
Zhmak, MN ;
Bertrand, D ;
Tsetlin, V ;
Sixma, TK ;
Smit, AB .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2005, 12 (07) :582-588
[4]   alpha-Conotoxin imperialis I inhibits nicotine-evoked hormone release and cell proliferation in human neuroendocrine carcinoma cells [J].
Codignola, A ;
McIntosh, JM ;
Cattaneo, MG ;
Vicentini, LM ;
Clementi, F ;
Sher, E .
NEUROSCIENCE LETTERS, 1996, 206 (01) :53-56
[5]   β2 subunit contribution to 4/7 α-conotoxin binding to the nicotinic acetylcholine receptor [J].
Dutertre, S ;
Nicke, A ;
Lewis, RJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (34) :30460-30468
[6]   Computational approaches to understand α-conotoxin interactions at neuronal nicotinic receptors [J].
Dutertre, S ;
Lewis, RJ .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2004, 271 (12) :2327-2334
[7]   Toxin insights into nicotinic acetylcholine receptors [J].
Dutertre, Sebastien ;
Lewis, Richard J. .
BIOCHEMICAL PHARMACOLOGY, 2006, 72 (06) :661-670
[8]   α-conotoxins:: Nicotinic acetylcholine receptor antagonists as pharmacological tools and potential drug leads [J].
Dutton, JL ;
Craik, DJ .
CURRENT MEDICINAL CHEMISTRY, 2001, 8 (04) :327-344
[9]  
Dwoskin LP, 2001, J PHARMACOL EXP THER, V298, P395
[10]  
ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224